Wednesday, February 2 2011

MIVAC Development receives verification grants from Innovationskontor Väst for both the AβCCTM-project and for the tolerance inducing Re-TolerogenTM platform.

In the AβCCTM-project the financing will enable commercial verification of the project, with focus on a structured IPR-investigation and mapping of potential financiers and interested pharmaceutical companies.

For the tolerance inducing Re-TolerogenTM platform the financing will be used to further verify the strength of the technology by performing studies comparing the treatment to the currently established treatment on the market.